A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

Inclusion Criteria: * Diagnosis of definite IA outside the pulmonary system or definite or probable pulmonary IA * Life expectancy: greater than 72 hours Exclusion Criteria: * Pregnant female * Hypersensitivity to anidulafungin or echinocandin therapy * Hypersensitivity to Tween 80 (polysorbate 80) or tartaric acid * Hypersensitivity to amphotericin B deoxycholate or any other constituents of AmBisome unless, in the opinion of the investigator, the benefit of therapy outweighs the risk. * Aspergilloma-in the absence of invasive disease * Abnormal blood chemistries: Bilirubin \> 3 times the upper limit of normal; AST (aspartate aminotransferase) or ALT (alanine aminotransferase)\> 5 times the upper limit of normal * Greater than five days of therapeutic doses of systemic therapy for the current Aspergillus-associated condition or a cumulative dose of more than 5 mg/Kg of amphotericin, more than 25 mg/Kg of a lipid formulation of amphotericin, or more than 2g of itraconazole for the current condition. Prophylactic use of azoles or amphotericin is acceptable. * Less than 4 weeks since prior participation in an investigational drug or device study, with the exception of cytotoxic, antiretroviral agents and therapies for AIDS-related opportunistic infections.